With Contracts and IND Application in Hand, Cellceutix Nears Clinical Trials for New Cancer Drug

Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, would like to update shareholders on recent developments regarding the impending clinical trials for Kevetrin(TM), the Company’s novel anti-cancer compound. The contracts for the clinical trials to be hosted by a world- renown cancer center have been received and reviewed, and are slated to be back at the clinical site by the end of the week. The 3,000-page Investigational New Drug (IND) application has been reviewed and is ready for printing and binding. Stability testing has been completed for the manufactured materials in dose form and are now in hand for the commencement of clinical trials.

“It’s been a long road, but the light at the end of the tunnel is now bright,” commented Cellceutix CEO Leo Ehrlich. “As CEO and a significant investor in Cellceutix, I can’t possibly express how pleased I am with our position at this moment as we seek to make our mark on the future of cancer therapies. We are ready.”

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix’s actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix’s actual results to differ from its forward-looking statements include: Cellceutix’s current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix’s ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix’s SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin, KM133, and KM-391 have not been studied in humans at this time. The Company’s positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

Contact:

Cellceutix Corp.
Leo Ehrlich
(978) 236-8717

Cellceutix (CTIX) Stock Quote and News:

---

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated on several occasions for news dissemination and journalism services from Cellceutix Corporation and holds a total of 100,000 shares of 144 restricted stock of Cellceutix Corporation, none of which has been sold to date, nor intends to be sold in the near term. Prior compensation is listed in our full disclosure. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.